Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 16/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 13/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.50 |
| ▸ | RPS6KA1 | Q15418 | 3/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | AKT1 | P31749 | 8/20 | 0.49 |
| ▸ | AKT2 | P31751 | 8/20 | 0.49 |
| ▸ | AKT3 | Q9Y243 | 8/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | PRKACA | P17612 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | MARK3 | P27448 | 1/20 | 0.47 |
| ▸ | GRK5 | P34947 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720973 | 0.83 | ROCK1 (0.54) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4718346 | 0.82 | RPS6KA5 (0.62) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4714299 | 0.81 | RPS6KA5 (0.59) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4714293 | 0.81 | RPS6KA5 (0.59) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4717393 | 0.80 | RPS6KA5 (0.60) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4761981 | 0.79 | RPS6KA5 (0.59) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4716140 | 0.76 | RPS6KA5 (0.60) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| Hydrochloric Acid SCHEMBL4717365 | 0.76 | RPS6KA5 (0.59) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4000617 | 0.75 | RPS6KA5 (0.58) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4717261 | 0.74 | RPS6KA5 (0.68) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689393-A4 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | claimed |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | LEE DENNIS | 2007-05-31 | — | — | US | claimed |
| JP-2007507547-A | — | — | 2007-03-29 | — | — | JP | claimed |
| EP-1689393-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | claimed |
| WO-2005037198-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | claimed |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | LEE DENNIS | 2007-05-31 | — | — | US | disclosed |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | LEE DENNIS | 2007-05-31 | — | — | US | disclosed |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | LEE DENNIS | 2007-05-31 | — | — | US | disclosed |
| WO-2005037198-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | TNK2, CDC42BPB, CDC42BPA | RPS6KA5 117/4885ROCK1 4/4885RPS6KB1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.